| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Morphine salts (2) [central nervous system use] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Levorphanol tartrate [anesth] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Meptazinol [anesthesia] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Morphine salts [anesthesia] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Nalbuphine hydrochloride [anesthesia] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Papaveretum [anesthesia] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Papaveretum 10mg/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Papaveretum 20mg/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Papaveretum injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Pethidine hydrochloride [anesthesia] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Phenoperidine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Mixed opium alkaloids |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Fentanyl 1.6 mg oromucosal lozenge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely fentanyl 1.2 milligram/1 each conventional release oromucosal lozenge (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely fentanyl 800 microgram/1 each conventional release oromucosal lozenge (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely fentanyl 600 microgram/1 each conventional release oromucosal lozenge (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely fentanyl 400 microgram/1 each conventional release oromucosal lozenge (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Fentanyl 200 microgram oromucosal lozenge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butorphanol tartrate 10 milligram/1 milliliter conventional release nasal spray (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| methadonhydrochlorid 40 mg dispergibel tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely methadone hydrochloride 2 milligram/1 milliliter conventional release oral solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydromorphone hydrochloride 1 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydromorphonhydrochlorid 5 mg/5 ml oral væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydromorphone hydrochloride 3 milligram/1 each conventional release rectal suppository (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Morphine sulfate 30 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 2 mg/ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 4 mg/ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 5 mg/ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 8 mg/ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 25mg/ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 50 mg/ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Morphine sulfate 5 mg rectal suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| oxycodonhydrochlorid 160 mg tablet med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely oxycodone hydrochloride 1 milligram/1 milliliter conventional release oral solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing oxymorphone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| oxymorphonhydrochlorid suppositorium a 5 mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Fentanyl 300 microgram oromucosal lozenge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| levomethadylacetathydrochlorid 10 mg/ml oral opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| pethidinhydrochlorid 50 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| pethidinhydrochlorid 25 mg/1 ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| pethidinhydrochlorid 75 mg/1 ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing sufentanil (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| bromazin + codein 12,5 mg/5 ml/10 mg/5ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| brompheniraminmaleat + codeinphosphat + phenylpropanolaminhydrochlorid 2 mg/5 ml 10 mg/5 ml 12,5 mg/5 ml syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| butorphanoltartrat 2 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| butorphanoltartrat 1 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 7.5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| sufentanilcitrat 50 µg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely dextropropoxyphene napsylate 100 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Oxycodone hydrochloride 20 mg/mL oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| methadonhydrochlorid 10 mg/ml oral opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| pethidinhydrochlorid 75 mg/1,5 ml opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| pethidinhydrochlorid 75 mg/ml opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| pethidinhydrochlorid 25 mg/0,5 ml opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydromorphonhydrochlorid 1 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydromorphonhydrochlorid 2 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydromorphonhydrochlorid 4 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydromorphonhydrochlorid 10 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydromorphonhydrochlorid 100% pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydromorphone hydrochloride 3 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydromorphonhydrochlorid 1 mg/ml væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydromorphonhydrochlorid 250 mg pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Oxycodone hydrochloride 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Oxycodone hydrochloride 15 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Oxycodone hydrochloride 30 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| pethidinhydrochlorid 50 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| pethidinhydrochlorid 100 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Fentanyl citrate 400mcg lozenge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| alfentanilhydrochlorid 500 µg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| nalbuphinhydrochlorid 20 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| codeinphosphat 4,56 mg/ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| codeinphosphat 5 mg/ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Morphine sulfate 4 mg/mL oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Morphine sulfate 15 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 200 mg/20 ml opløsnig |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 1 mg/ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 0,5 mg/ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 10 mg/10 ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 500 mg/20 ml opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Morphine sulfate 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Morphine sulfate 15 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Morphine sulfate 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| methadon 10 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely morphine sulfate 30 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Pethidine hydrochloride 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydromorphone hydrochloride 4 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydromorphone hydrochloride 2 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydromorphone hydrochloride 8 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Levorphanol tartrate 2 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| paracetamol 120 mg + alkohol 7%v v + codeinphosphat 12 mg eliksir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| paracetamol 120 mg + codeinphosphat 12 mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely codeine phosphate 15 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 5 mg and paracetamol 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 10 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 5 mg and paracetamol 500 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + hydrocodone bitartrate 500mg/7.5mg elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 7.5 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
FHIR